说的直白点,免疫治疗反应的生物标志物不是MSI,不是dMMR,甚至也不是TMB,而是肿瘤细胞产生的Neoantigen,肿瘤细胞产生的新生抗原则是可以直接评估免疫治疗响应的。 The ultimate biomarker for immunotherapeutic response is not MSI(dMMR) or even the mutational burden (TMB) but the presence of immunogenic neoepitop...
However, correlation of survival with mutation and neoantigen burden has not been reported for cancers of lower mutational burden such as MM. Early results of single-agent checkpoint inhibitors in MM are underwhelming. Single-agent nivolumab (anti-PD-1 monoclonal antibody) had no objective responses ...
Cancer cells with high amount of neoantigens are more likely to be captured by immune cells and thus patients with high Tumor Mutation Burden(TMB) and high Tumor Neoantigen Burden(TNB) are estimated to be prone to ICIs treatment. HLA class Ⅰ is one of the main factors affecting the ...
one can use putative neoantigen peptide sequences to guide personalised cancer vaccines design; one can define a metric "tumor neoantigen burden" (TNB) derived from neoantigen abundancy and/or quality that would relate to the the immune system activity in cancer suppression. It can be used, for...
-t Flag to turn off a neoantigen burden summary table. Default=True.Input filesVCF file(s). A standard vcf file with a patient identifier as the title of the .vcf. Several vcf files can be specified in the same directory. An hla file with the following tab delimited format: Note, ...
fusion neoantigens are more likely to induce stronger immune response than the neoantigens produced by SNVs and INDELs, and the neoantigen produced by frameshift fusion has better immunogenicity than the in-frame fusion neoantigen (Table2). Similar to the candidate neoantigen burden of SNVs and ...
Although MS has sensitivity limits and biases, and likely underestimated the true neoantigen burden, this established a lower bound of the percentage of non-silent mutations that encode for presented neoantigens, which may be as low as 0.5%. This could be a reason for the poor responses of ...
Given an example dataset we show how NeoPredPipe is able to rapidly provide insights into neoantigen heterogeneity, burden, and immune stimulation potential. Conclusions: Through the integration of widely adopted tools for neoantigen discovery NeoPredPipe offers a contiguous means of processing single ...
We will present in detail the existing immunotherapeutic options that exploit the neoantigen burden of tumors encompassing both preclinical efforts that provided convincing technological proof-of-concept and the current clinical studies confirming the potential of neoantigen-directed immunotherapies. 展开 ...
597#Background:Most patients (pts) with urothelial cancer (UC) treated with immune checkpoint inhibitors (ICIs) do not respond. Given that features associated with restrained antitumor immunity and high neoantigen burden have correlated with response to ICI, stimulating antitumor immunity with neoantigen...